These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 10762837)

  • 1. Local Drug Delivery for Restenosis and Thrombosis Ñ Progress?
    Gonschior P
    J Invasive Cardiol; 1998 Oct; 10(8):528-532. PubMed ID: 10762837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Local drug administration systems, preclinical and clinical use: perspectives and limitations].
    Gonschior P; Wilensky R; March K; Höfling B
    Z Kardiol; 1996 Mar; 85(3):155-65. PubMed ID: 8659193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of locally delivered conventional drug therapies.
    Camenzind E; Kutryk MJ; Serruys PW
    Semin Interv Cardiol; 1996 Mar; 1(1):67-76. PubMed ID: 9552496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local drug delivery in restenosis injury: thermoresponsive co-polymers as potential drug delivery systems.
    Kavanagh CA; Rochev YA; Gallagher WM; Dawson KA; Keenan AK
    Pharmacol Ther; 2004 Apr; 102(1):1-15. PubMed ID: 15056495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-eluting stent: the emerging technique for the prevention of restenosis.
    Sheiban I; Carrieri L; Catuzzo B; Destefanis P; Oliaro E; Moretti C; Trevi GP
    Minerva Cardioangiol; 2002 Oct; 50(5):443-53. PubMed ID: 12384626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronary restenotic reduction of drug-eluting stenting may be due to its anti-inflammatory effects.
    Li JJ; Li J; Nan JL; Li Z; Zhen X; Mu CW; Dai J; Zhang CY
    Med Hypotheses; 2007; 69(5):1004-9. PubMed ID: 17499449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug release kinetics from stent device-based delivery systems.
    Tesfamariam B
    J Cardiovasc Pharmacol; 2008 Feb; 51(2):118-25. PubMed ID: 18287878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local administration of NF-kappa B decoy oligonucleotides to prevent restenosis after balloon angioplasty: an experimental study in New Zealand white rabbits.
    Kalinowski M; Viehofer K; Hamann C; Barry JJ; Kleb B; Klose KJ; Wagner HJ; Alfke H
    Cardiovasc Intervent Radiol; 2005; 28(3):331-7. PubMed ID: 15886949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for local drug delivery.
    Eccleston DS; Horrigan MC; Ellis SG
    Semin Interv Cardiol; 1996 Mar; 1(1):8-16. PubMed ID: 9552480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local catheter-based delivery of antithrombotic or antiproliferative drugs: a new concept for prevention of restenosis.
    Herdeg C; Goehring-Frischholz K; Zuern C; Geisler T; Hartmann U; Hoevelborn T; Haase KK; Gawaz M
    Thromb Res; 2008; 123(2):236-43. PubMed ID: 18452977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical and clinical experience in vascular gene therapy: advantages over conservative/standard therapy.
    Nikol S; Huehns TY
    J Invasive Cardiol; 2001 Apr; 13(4):333-8. PubMed ID: 11287726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local paclitaxel delivery after coronary stenting in an experimental animal model.
    Dommke C; Haase KK; Süselbeck T; Streitner I; Haghi D; Metz J; Borggrefe M; Herdeg C
    Thromb Haemost; 2007 Sep; 98(3):674-80. PubMed ID: 17849059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of local molsidomine delivery from a hydrogel-coated angioplasty balloon catheter in the atherosclerotic porcine model.
    Rolland PH; Mekkaoui C; Palassi M; Friggi A; Moulin G; Piquet P; Bartoli JM
    Cardiovasc Intervent Radiol; 2003; 26(1):65-72. PubMed ID: 12491015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local vascular toxicokinetics of stent-based drug delivery.
    Tesfamariam B
    Toxicol Lett; 2007 Jan; 168(2):93-102. PubMed ID: 17169513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Optimal platelet inhibition after coronary stent implantation. Current status].
    Silber S; Hoffmeister HM; Bode C
    Herz; 2008 Jun; 33(4):244-53. PubMed ID: 18581073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is inflammation a contributor for coronary stent restenosis?
    Li JJ; Nie SP; Zhang CY; Gao Z; Zheng X; Guo YL
    Med Hypotheses; 2007; 68(5):945-51. PubMed ID: 17045418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel approaches to reduce restenosis.
    Beyar R
    Ann N Y Acad Sci; 2004 May; 1015():367-78. PubMed ID: 15201175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymeric endoluminal gel paving: therapeutic hydrogel barriers and sustained drug delivery depots for local arterial wall biomanipulation.
    Slepian MJ
    Semin Interv Cardiol; 1996 Mar; 1(1):103-16. PubMed ID: 9552500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.